

Fifth EULAR Course on Systemic Lupus Erythematosus
Preliminary Program

Pisa, Italy
September 4-9, 2011

Sunday, September 4, 2011

17.00-18.00		Arrival and registration of participants
18.00- 18.30	S. Bombardieri	Welcome and course presentation
18.30-19.30	R. Danesi	New frontiers in modern rheumatology: the pharmacogenomics

Monday, September 5, 2011

Morning

What a clinician should know about the pathogenesis of SLE

9.00-9.30	M. Galeazzi	The genetic of SLE
9.30-10.00	R. Voll	Cellular immunity in SLE
10.00-10.30	P. Migliorini	Pathogenetic antibodies in SLE
10.30-11.00	<i>Coffee break</i>	
11.00-11.30	M. Botto	The role of complement in the pathogenesis of SLE
11.30-12.00	A. Doria	An overview of SLE pathogenesis: specific organ involvement and potential therapeutic targets
12.00- 12.30	Y. Shoenfeld	Vaccination and autoimmune diseases
12.30-13.00		<i>Clinical exercise: the use of a core set in clinical practice</i>

Afternoon

The therapeutic armamentarium in SLE

14.30-15.00	M. Schneider	“Traditional drugs” in SLE. Focus on immunosuppressive drugs
15.00-15.30	M. Ostensen	Drug therapy and toxicity in pregnancy and lactation
15.30-16.00	M. Mazzantini	Osteoporosis and SLE
16.00-17.00		<i>Discussion of clinical cases</i>

Tuesday, September 6, 2011

Morning

Future trends in the management of SLE and comorbidities

9.00-9.30	P.L. Meroni	Cardiovascular involvement in SLE
9.30-10.00	C.M. Montecucco	Infections and SLE

10.00-10.30	<i>Coffee break</i>	
10.30-11.00	J. van Laar	Stem cell therapy of SLE
11.00-11.30	M. Ward	Pitfalls of trials in SLE, observational studies versus randomized controlled trials
11.30-12.00	N. Costedoat	Hydroxychloroquine in the treatment of SLE
12.00-13.00		<i>Discussion of clinical cases</i>

Afternoon

Skin involvement

14.30-15.30		<i>Presentation of clinical cases</i>
15.30-16.00	V. Werth	Cutaneous manifestations in lupus erythematosus and differential diagnosis
16.00-16.30	A. Kuhn	Diagnosis and treatment of cutaneous manifestations in lupus erythematosus

Wednesday, September 7, 2011

Morning

Kidney involvement

9.00-9.30	D. Jayne	Laboratory assessment in lupus nephritis in routine clinical practice
9.30-10.00	G. Moroni	Clinical features and prognostic factors in LN
10.00-10.30	F. Houssiau	Therapeutic algorithms in lupus nephritis
10.30-11.00		<i>Coffee break</i>
11.00-11.30	M. Cutolo	Hormones/Vitamin D in SLE
11.30-12.00	J.W.J. Bijlsma	Corticosteroids: principles of therapy and monitoring
12.00-12.30	D. Boumpas	New drugs development in SLE
12.30-13.00		<i>Discussion of clinical cases</i>

Afternoon : FREE

Thursday, September 8, 2011

Neuropsychiatric lupus (NPSLE)

9.00-9.30	P. Meroni	Pathogenesis of neuropsychiatric lupus
9.30-10.00	A. Tincani	The clinical spectrum of neuropsychiatric lupus
10.00-10.30	G. Castellino	Neuroimaging in the diagnosis of neuropsychiatric lupus
10.30-10.45		A simple questionnaire to screen patients for neuropsychiatric lupus
10.45- 11.15		<i>Coffee break</i>

11.15-11.45	G. Bertias	The assessment of SLE patients with neuro-psychiatric lupus: EULAR recommendations
11.45-12.15	T. Huizinga	Treatment of neuropsychiatric lupus
12.15-13.00		<i>Discussion of clinical cases</i>

Afternoon

Pregnancy and SLE

14.30-15.00	F. Strigini	Outcome of pregnancy in patients with SLE
15.00-15.30	M. Khamashta	Proposal of therapeutic approaches to active SLE during pregnancy
15.30-16.00	A. Brucato	Neonatal lupus and outcome of babies of SLE patients
16.00-16.30	A. Martini	Juvenile lupus

Friday, September 9, 2011

Morning

Assessment of patients in routine clinical practice

9.00- 9.30	M. Mosca	Activity, damage and response indices in SLE, an overview
9.30-10.00	P.C. Sarzi Puttini	Fatigue and SLE
10.00-10.30	G. Valesini	Long term prognosis and causes of death in SLE
10.30- 11.00		<i>Coffee break</i>
11.00-11.30	J. Yazdany	Quality of care in systemic lupus erythematosus
11.30-12.00	M. Mosca	Monitoring SLE in routine clinical practice: from the EULAR Recommendations to the development of a core set to be used in routine clinical practice
12.30-13.00		<i>Discussion of clinical cases</i>

Afternoon

SLE and related conditions

14.30-15.00	A.G. Tzioufas	SLE and Sjogren's syndrome
15.00-15.30	S. Bombardieri	Undifferentiated connective tissue diseases
15.30-16.00	C. Tani	SLE and RA: rhusus
16.00-16.30	R. Cervera	SLE and anti-phospholipid syndrome
16.30-17.00	M. Aringer	Mixed connective tissue disease
17.00-17.30		Conclusion of the Course and CME questionnaires